Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

Clinical trial NCT06816927 · RECRUITING

Trial details

NCT number: NCT06816927
Sponsor: Duke University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Newly Diagnosed Glioblastoma

Start date: 2025-11-28
Primary completion: 2029-06-01
Enrollment: 92

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.